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1. Introduction 
Genetic mutation has made great contributions to determining protein structure and 
function, viral pathogenesis, biological engineering, and vaccine development [1-9]. In order 
to alter genetic information, gene mutation (also called mutagenesis) can be achieved by 
many different methods. The process of mutagenesis can occur naturally, as the root of 
evolution; by mutagens, such as chemicals or radiation; and experimentally, by laboratory 
techniques [10-13]. Current experimental mutagenesis methods can be generally classified 
into random and directed mutation. 
Experimentally directed mutagenesis methods include: insertional mutagenesis [14], PCR 
mutagenesis [15, 16], signature tagged mutagenesis [17], site-directed mutagenesis [18, 19] 
and transposon mutagenesis [20-22]. Different procedures are involved in traditional 
mutagenesis, including molecular cloning that depends on preparations of vector and 
inserted DNA fragments and ligations. This traditional mutagenesis method is not only 
time-consuming, but also labor intensive, and modern advancements in mutagenesis have 
overcome these obstacles. The development of the Bacterial Artificial Chromosome (BAC) 
clone of large DNA viruses was a breakthrough in the viral mutagenesis field. The BAC 
clone of a virus can be maintained stably and propagated inside a bacterial cell, which 
allows for easy manipulation of the viral genome. Any required mutation can be easily and 
rapidly achieved inside the E. coli cell and this mutation can be verified before making 
recombinant virus [23-27]. Since the development of this novel method for construction of 
recombinant viruses, detailed functional study of virus genome has been done using this 
specific BAC recombinatory mutagenesis approach [23-27].  
Recombination is an important procedure in experimental mutagenesis. There are two 
recombination systems that are often used: DNA sequence-specific recombinase-driven 
recombination and homologous recombination. The DNA sequence-specific recombinase-
driven recombination includes Cre-Lox and FLP-FRT recombination systems [28-36]. Cre-
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Lox system depends on Cre recombinase that specifically recognizes lox P (locus of X-over 
bacteriophage P1) sites, 34-basepair (bp) specific sequences and results in recombination by 
the excision of intervening DNA sequence and joining of site-specific ends. FLP-FRT 
involves the recombination of sequences between short flippase recognition target (FRT) 
sites (also a 34-bp DNA sequence) by the flippase recombination enzyme (FLP or Flp) 
derived from Saccharomyces cerevisiae yeast. After recombination, one copy of the specific 
DNA sequence will remain in the vector, which will cause potential problems for further 
mutagenesis, DNA stability and, therefore, is not suitable for some applications, such as 
vaccine development. In addition, BAC sequence excision methods should be carefully 
considered, depending upon the design of the BAC. For example, it will become problematic 
if both the BAC vector and gene-specific antibiotic marker contain the same flanking 
excision sequences (such as loxP) because this is likely to cause the removal of a much larger 
sequence of genomic DNA than originally intended. 
Homologous recombination is a type of genetic recombination in which nucleotide 
sequences are exchanged between two identical sequences of DNA [37, 38]. Wild-type E. 
coli is ineffective at inducing homologous recombination in foreign DNA because linear 
DNA is commonly degraded by RecBCD exonuclease. In order to circumvent this 
problem, SW102 strains were developed that contain a temperature-sensitive ┣ prophage 
encoding one gene to temporarily repress RecBCD (gam), as well as two genes (exo and 
beta) utilized for homologous recombination via double-strand break repair [38]. More 
specifically, exonuclease degrades DNA from the 5 end of double-strand break sites, 
while Beta binds to and protects the 3 from further degradation [39, 40]. These overhangs 
from double-strand breaks allow recombination between viral and plasmid DNA. Because 
the ┣ phage is temperature sensitive (due to the expression of a temperature-sensitive ┣ cI-
repressor), linear DNA uptake and recombination can occur within a few minutes when 
the cell-culture temperature is increased from 32 to 42C [38]. This allows the bacterial 
cells to function normally when grown at 32C. E. coli also require thousands of 
homologous base pairs in order for recombination to occur. Addition of the modified 
temperature-sensitive ┣ phage is important because this allows homologous 
recombination to occur within a relatively small region of the homologous sequence, 
which is important because BAC mutants are usually created using PCR-amplified gene 
sequences with about 40 base pairs of flanking sequences that are homologous to the viral 
BAC [37]. 
PCR-based preparation for insertion of DNA provided convenience in performing 
mutagenesis studies. Differential PCR techniques enable researchers to make any 
mutation, as needed: large deletion, point mutation, substitution, insertion, non-sense 
mutation and shift-mutation. Allowing for the use of a positive and negative selection 
system is another advancement in the area of mutagenesis, especially when applied to 
site-directed mutagenesis when accuracy and precision are of high priority. There are 
multiple ways to carry out site-directed mutagenesis of a viral BAC. For example, 
selectable markers are necessary to isolate the successful mutation of a viral BAC, and 
selectable markers can be an antibiotic resistant gene (such as kanamycin or zeocin 
resistant genes) or a foreign metabolic gene (such as galK). In the case of a gene knockout, 
the foreign DNA usually contains a selectable marker flanked by a DNA sequence 
homologous to the flanking regions for the gene of interest. Around 40 bp of a flanking 
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sequence are typically used for homologous recombination. The viral BAC and the marker 
with homologous sequences are then inserted into E. coli via electroporation. Colonies 
with the BAC recombinant virus can be selected based upon selection markers and 
verified by PCR [27]. 
This protocol describes the use of the galK positive- and counter- selection schemes to make 
gene mutations (e.g. point mutations, deletions, and insertions) within viral BACs. This 
system includes only two steps of recombination within a modified bacterial strain, SW102 
[41], using selection and counter-selection media, and easily designed PCR. The SW102 
strain, derived from DY380 E. coli [38, 42, 43], differs from DY380 only in that the 
galactokinase (galK) gene of the galactose operon is defective in SW102 strain. When SW102 
bacteria are incubated on minimal media with galactose as the sole source of carbon, the 
bacteria cannot grow without galK supplied in trans [41]. When the galK gene is provided in 
trans, in this case it replaces a gene of interest, it can complement the defective galK gene in 
the bacteria and the bacteria can grow in minimal media with galactose, therefore, the first 
step is a positive selection. Later in the protocol, when galK is removed from the viral BAC 
and replaced with a mutated version of the original gene, a counterselection takes place in 
that clones containing galK will be negatively selected for by growing the bacteria on 
medium with a substance that produces a toxic intermediate only when a functional galK is 
present. 
This protocol explains in detail how to use the galK positive and counterselection strategies 
to make any desired mutations (e.g. point mutations, deletions, and insertions) based on 
plasmid or BAC. The modified plasmid or BAC will not contain any extra DNA sequence; 
therefore, it is referred to as a “seamless” mutation. 
2. Materials and methods 
Bacterium: E. coli SW102 strain (free reagents from Biological Resources Branch of NCI-
Frederick) [41] 
Plasmid: pgalK (free reagents from Biological Resources Branch of NCI-Frederick) [41] 
Luria-Broth (LB) medium 
Tryptone               10 g 
Yeast Extract            5 g 
NaCl                       10 g  
Dissolve components in distilled and deionized water (ddH2O) and adjust the total volume 
up to 1 liter.   
For LB agar: add agar to a final concentration of 1.5%. 
Heat the mixture to boiling to dissolve agar and sterilize by autoclaving at 15 psi, from 121-
124°C for 15 minutes. 
1X M9 medium (1 liter) 
6 g Na2HPO4 
3 g KH2PO4 
1 g NH4Cl 
0.5 g NaCl 
Dissolve components in ddH2O and make the total volume up to 1 liter.  Autoclave 
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M63 minimal plates 
1L 5X M63  
10 g (NH4)2SO4 
68 g KH2PO4 
2.5 mg FeSO4·7H2O 
Dissolve components in ddH2O and make the total volume up to 1 liter. Adjust to pH 7 with 
KOH. 
Autoclave 
Other Reagents 
0.2 mg/ml D-biotin (sterile filtered) (1:5000) 
20% galactose (autoclaved) (1:100) 
20% 2-deoxy-galactose (autoclaved) (1:100) 
20% glycerol (autoclaved) (1:100) 
10 mg/ml L-leucine (1%, heated, then cooled down and sterile filtered) 
25 mg/ml chloramphenicol in Ethanol (1:2000) 
1 M MgSO4·7H2O (1:1000) 
Procedure of making the M63 minimal plates:  
1. Autoclave 15 g agar in 800 ml H2O in a 2-liter flask. 
2. Add 200 ml autoclaved 5X M63 medium and 1 ml 1 M MgSO4·7 H2O.  
3. Adjust volume to 1 liter with H2O if necessary. 
4. Let cool down to 50°C (“hand touchable hot”), add 10 ml carbon source (final 
concentration 0.2%), 5 ml biotin (1 mg), 4.5 ml leucine (45 mg), and 500 µl 
chloramphenicol (final concentration 12.5 mg/ml) or other appropriate antibiotics. Pour 
the plates, 33-40 plates per liter. 
MacConkey indicator plates: 
Prepare MacConkey agar plus galactose according to manufacturer’s instructions. After 
autoclaving and cooling to 50°C, to one liter, add 500 µl chloramphenicol (final concentration 
12.5 mg/ml) or other appropriate antibiotics, and pour the plates, 33-40 plates per liter. 
3. Protocol 
3.1 Preparing SW102 that harbors plasmid or BAC 
Select the plasmid or BAC that contains the target gene and will be used as a vector for 
making mutations. Information about the vector, including antibiotic-resistance and the 
targeted gene, needs to be known. For example, to make any mutation of a gene in murine 
cytomegalovirus (MCMV), the BAC of SM3fr [46] is usually used.  SM3fr contains whole 
genome of MCMV with chloramphenicol resistance. The DNA sequence and gene structure 
of SM3fr have been published and can be accessed in public gene bank. 
3.1.1 Preparation of electrocompetent cells (Fig. 1. 1a) 
1. A 5-ml overnight culture of E. coli SW102 in LB medium will be prepared either from 
the frozen stock or from a single colony at 32°C or lower. The SW102 strain is resistant 
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to tetracycline (12.5 ┤g/ml), it is not necessary, but safe to include tetracycline in this 
step in order to exclude any possible contamination.  
2. The overnight LB culture of SW102 will be diluted by 1:50 by adding 0.5 ml of the 
overnight culture to an autoclaved 50 ml Erlenmeyer baffled flask with 25 ml LB, but 
first save 1 ml LB that will be used as a reference for measuring the OD600nm. The 
diluted SW102 in the flask will be incubated for 3-5 hrs with appropriate antibiotic 
selection in a 32°C shaking incubator until the density reaches an OD600nm of 0.6. At this 
point, a bottle of ice-cold 10% glycerol or autoclaved ddH2O needs to be prepared. (If 
the competent cells are to be used right away, use autoclaved ddH2O). The competent 
cells can be used right away or stored at -70°C for later use. 
3. When the OD600nm is 0.6, the flasks containing the bacteria will be cooled down in the 
ice water bath slurry for a minute or two and subsequently transferred into pre-cooled 
15 ml Falcon tubes. 
4. The bacteria will be centrifuged in a cold centrifuge (4°C) for 5 min at 5000 RPM 
(standard Beckman or Eppendorf centrifuge). 
5. All supernatant will be poured off and the centrifuge tubes will be briefly inverted on a 
paper towel, and 1 ml ice-cold ddH2O or 10% glycerol will be added to resuspend the 
pellet.  And the tube will be kept in the ice. The pellet will be resuspended in the ddH2O 
or 10% glycerol by gently shaking the tube in the ice-water bath (gently move the tubes 
around in circles while keeping them in the ice water slurry, this can take a while for 
the first time). When the cells are completely resuspended, another 9 ml ice-cold ddH2O 
or 10% glycerol will be added, the tube will be inverted for a couple of times, and 
centrifuged again for 5 minutes. 
6. The supernatant will be poured off and the pellet will be resuspended with 10 ml ice-
cold ddH2O or 10% glycerol, as in Step 5, resuspension should be much faster this time). 
7. The resuspended cells will be centrifuged once more, as in Step 5. 
8. The supernatant will be completely removed by inverting the tube on a paper towel (be 
careful that you do not lose the pellet). The pellet will be resuspended in 250 ┤l ice-cold 
10% glycerol. The competent cells can be used immediately for transformation or 
aliquoted and stored at -80ºC (volume should be around 50 ┤l). 
3.1.2 Transformation by electroporation (Fig. 1. 1b) 
1. Plasmid or BAC DNA will be transformed into the SW102 competent cells made in Step 
1.1. The freshly made or stored electrocompetent cells will be mixed with 1-5 ┤g DNA. 
The mixture of cells and DNA will be transferred to a pre-cooled 0.1 cm cuvette. It is 
important that the DNA solution contains low salt because high salt can cause electric 
shock during electroporation. 
2. The cuvette will be placed into the electroporator power source and cuvette holder (Bio-
Rad). The conditions for transformation are set according to the strain. For SW102 cells, 
use 25 mFD, 200 W, and 1.8 kV. The time constant (tau value) should be 3-4 msec. After 
the electroporation, the bacteria will be transferred immediately to a tube with 1 ml LB 
medium and incubated at 32°C in a shaking water bath for 1 hr. 
3. The incubated bacteria will be smeared onto LB agar plates that contain appropriate 
antibiotics.  The transformed bacteria on selective LB agar will grow as colonies after 
incubation at 32°C for 18-24 hrs.  
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4. The generated SW102 harboring plasmid or BAC will be verified by picking up a 
colony, isolating the DNA by BAC Minipreparation (see Step 1.3.) and detecting the 
DNA with PCR analysis of the BAC (Fig. 3) and/or restriction enzyme digestion (Fig. 
4). This plasmid- or BAC-harboring SW102 will be given a name and used to make 
desired mutation of the target gene. For example, if the SW102 harbors MCMV BAC 
SM3fr, it will be called SW102_SM3fr. 
 
 
Fig. 1. Summary of the galK-based mutagenesis in E. coli SW102. 1a. Prepare 
electrocompetent (E.C.) SW102 E. coli. 1b. Electroporate WT virus BAC into 
electrocompetent SW102. 2a. Prepare galK cassette by PCR with a set of primers conferring 
sequence homology to the viral BAC sequences flanking geneX. 2b. Prepare 
electrocompetent SW102 E. coli harboring WT viral BAC and activate defective ┣ phage 
recombination system by shaking in a 42ºC water bath for 15 minutes. 3. Electroporate the 
galK-expressing cassette into recombination-activated electrocompetent SW102 strain 
harboring WT BAC. 4. Upon homologous recombination, geneX is replaced by galK.  
5. Confirm presence of galK by growing bacteria on M63 plates with galactose as the sole 
source of carbon and antibiotic, selecting colonies to screen on MacConkey agar with 
galactose as the sole source of carbon. The galK-containing recombinant clones will produce 
red colonies on MacConkey agar with galactose. 6. Select red colony from screening process 
to verify by PCR and continue. 7a. Prepare geneY cassette (PCR cassette containing desired 
mutation in geneX, referred to as geneY). 7b. From red colony selected in Step 5, prepare 
electrocompetent SW102 harboring galK mutant BAC and activate defective ┣ phage 
recombination system, as in 2b. 8. Electroporate geneY cassette into electrocompetent and 
recombination-activated SW102 containing galK mutant clone. 9. Upon homologous 
recombination, galK is replaced by geneY. 10. Grow bacteria on M63 with glycerol, DOG and 
antibiotic agar plates. 11. Select colony and verify for production of virus. 
3.1.3 BAC minipreparation 
The following protocol is usually used and works very well for generating BAC DNA for 
initial analysis:  
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1. 5 ml overnight LB culture with chloramphenicol (almost all known BACs are 
chloramphenicol resistant) in a 15-ml Falcon tube is pelleted, and the supernatant is 
removed.  
2. Then the pellet is dissolved in 250 ┤l buffer P1 (Miniprep kit, Qiagen, CA) and 
transferred to an Eppendorf tube.  
3. The bacteria are lysed in 250 ┤l P2 buffer with gently mixing and incubating for 5 min at 
room temperature.  
4. The lysate is neutralized with 250 ┤l buffer P3 (also called N3 buffer), followed by 
mixing and incubating on ice for 5 min.  
5. The supernatant is cleared by two rounds of centrifugation at 13,200 RPM for 5 min in a 
small Eppendorf centrifuge (or other model tabletop centrifuge). Each time the 
supernatant is transferred to a new tube.  
6. The DNA is precipitated by adding 750 ┤l isopropanol, mixing and incubating on ice 
for 10 min, and centrifugation for 10 min at 13,200 RPM in a small Eppendorf centrifuge 
(or other model tabletop centrifuge). 
7. The pellet is washed once in 70% ethanol and the air-dried pellet is dissolved in 50-100 
┤l TE buffer. The isolated BAC DNA can be used for 1) restriction analysis, 2) PCR 
analysis and 3) DNA sequencing analysis. 
3.2 Positive selection to replace the targeted DNA with galK gene 
3.2.1 PCR to generate the galK cassette (Fig. 1. 2a) 
1. Design primers with 50 bp homology flanking the desired site to be modified. The 3’ 
end of these primers will bind to the galK cassette. For example, if a single base pair (bp) 
mutation will be generated, the homology arms should extend 50 bp on either side of 
the target bp. If the target bp is not included in the arms, it will result in a deletion of 
that base pair in the first step. If the target bp was changed into another bp in the arm, it 
will result in single bp mutation. If a small or a large deletion will be made, design the 
galK primers so that the deletion is made already in the first step. The primers should be 
as follows: 
Forward: 5’ 50bp homology: CCTGTTGACAATTAATCATCGGCA-3’ 
Reverse: 5’ 50bp homology complementary strand: TCAGCACTGTCCTGCTCCTT-3’ 
2. Plasmid pgalK will be used for PCR to amplify the galK gene using the primers 
designed as above and a proofreading DNA polymerase. It is important to use this type 
of DNA polymerase because the two-step substitution in the procedure will use PCR 
products and accuracy is a high priority. DNA template for PCR is the pgalK plasmid. 
PCR can be started at 94°C for 4 min to denature the template, followed with 30 cycles 
of three temperatures: 94°C, 15 sec; 60°C, 30 sec; 72°C, 1 min; and the PCR will be 
extended for 7 min at 72°C.  
3. When the PCR is finished, 1-2 µl DpnI (New England Biolabs, MA) should be added 
into each 25 µl reaction that is mixed and incubated at 37°C for 1 hour. This step serves 
to remove any plasmid template; plasmid is methylated so that DpnI can degrade it, 
PCR products are not methylated so DpnI cannot degrade it. Finally, the DpnI-digested 
PCR product will be separated in agarsoe gel and purified from gel. The PCR product 
will be eluted with 50 ┤l ddH2O, 10-30 ng will be used for transformation. 
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3.2.2 Preparation of electrocompetent cells harboring BAC 
SW102 E. coli strain has a defective ┣ prophage that, when activated, can produce 
recombinase. These activated and electrocompetent SW102 harboring plasmid or BAC DNA 
(e.g. SW102_SM3fr) (Fig. 1. 2b) will be prepared from the electrocompetent SW102 harboring 
plasmid or BAC DNA prepared in Step 1.2 of the protocol. The procedure is as follows: 
1. Inoculate an overnight culture of SW102 cells containing the BAC in 5 ml LB with 
appropriate antibiotics (e.g. SW102_SM3fr in LB with chloramphenicol) at 32°C. 
2. Next day, add 0.5 ml of the overnight SW102 harboring plasmid or BAC DNA in 25 ml 
LB with antibiotics in a 50-ml baffled conical flask and incubate at 32°C in a shaking 
water bath to an OD600nm of approximately 0.6 (0.55-0.6). This usually takes 3-4 hrs. 
During this time, turn on two shaking water baths: one at 32°C, the other at 42°C. Make 
ice/water slurry and pre-chill 50 ml of ddH2O. 
3. When the OD600nm of SW102 harboring plasmid or BAC DNA culture reaches 0.6, 
transfer 10 ml of the culture to another baffled 50-ml conical flask and heat-shock at 
42°C for exactly 15 min in a shaking water bath. This step is to induce SW102 to 
produce recombinase. The remaining culture is left at 32°C as the un-induced control. 
4. After 15 min induction, the SW102 in two flasks (10 ml induced and 10 ml un-induced) 
are briefly cooled in ice-water bath and then transferred to two 15-ml Falcon tubes and 
centrifuged at 4°C. It is important to keep the bacteria as close to 0°C as possible in 
order to get high efficiency competent cells. 
5. Pour off all of the supernatant and resuspend the pellet in 1 ml ice-cold autoclaved 
ddH2O by gently swirling the tubes in the ice-water bath slurry (no pipetting). This step 
may take a while. When the cells are resuspended, add another 9 ml ice-cold autoclaved 
ddH2O. Pellet the samples again as in Step 1.4. 
6. Resuspend the pellet again with I ml of ice-cold autoclaved ddH2O by gently swirling 
and then add 9 ml ddH2O. The bacteria are centrifuged again, as above. 
7. After the second washing and centrifugation step, all supernatant must be removed by 
inverting the tubes on a paper towel, and the pellet is resuspended in approximately 50 
┤l of ice-cold ddH2O and is kept on ice until electroporated with PCR product. If the 
electrocompetent cells are prepared with 10% glycerol, the aliquots can be made and 
saved at -80°C for later use.  
3.2.3 Electroporation of galK cassette 
1. 25 ┤l of electrocompetent SW102 cells harboring plasmid or BAC DNA and 10-30 ng of 
PCR amplified galK cassette will be added to a 0.1 cm cuvette (BioRad). Electroporation 
will be carried out at 25 mF, 1.75 kV, and 200 ohms (Fig. 1. 3). After reaction, 1 ml LB 
will be immediately added to the cells, and the cells will be cultured at 32°C for 1 hour 
in a shaking water bath. 
2. After the recovery incubation, the bacteria are washed twice with M9 buffer as follows: 
1 ml of the culture is centrifuged in an Eppendorf tube at 13,200 RPM for 15 sec. Then 
the supernatant is removed with a pipette. The pellet is resuspended with 1 ml M9 
buffer, and pelleted again. This washing step will be performed once more. After the 
second wash, the supernatant will be removed and the pellet will be resuspended in 1 
ml M9 buffer. A serial of dilutions in M9 buffer will be made (100 ┤l, 100 ┤l of a 1:10 
dilution, and 100 ┤l 1:100) and plated onto M63 minimal media plates with galactose, 
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leucine, biotin, and appropriate antibiotics (Fig. 1. 5). It is important to remove any rich 
media from the culture prior to selection on minimal media by washing the bacteria in 
M9 buffer. The uninduced SW102 will be plated as a control.  
3. The plates will be incubated for 3 days at 32°C in a cabinet-type incubator. Colonies will 
be visible at the beginning of third day and be able to be picked up at the end of that day. 
4. Pick up a few colonies and streak the colonies onto MacConkey agar plates with 
galactose, indicator and appropriate antibiotics to obtain single colonies (Fig. 1. 5). The 
colonies appearing after the 3 days of incubation should be galK positive, but in order to 
get rid of any galK negative contaminants (usually called hitch-hikers), it is important to 
obtain single, bright red colonies before proceeding to next step (Fig. 1. 6). galK negative 
colonies will be white or colorless and the galK positive bacteria will be bright red or 
pink due to a pH change resulting from fermented galactose after an overnight 
incubation at 32°C (Fig. 2). 
5. Pick up a few bright red (galK positive) colonies and inoculate in 5 ml LB + antibiotics 
and incubate overnight at 32°C. There is normally no need to further characterize the 
clones. But the galK positive clones can be Miniprepared (Step 1.3) and verified by PCR 
using primers that flank the site of the galK gene (Fig. 3): 
Forward: 5’ CTGTTGACAATTAATCATCGGCA-3’  
Reverse: 5’ TCAGCACTGTCCTGCTCCTT-3’  
The recombinant galK clones should be named for storage. Take MCMV BAC as an example: 
SW102_SM3fr_XgalK is the name of the bacteria and SM3fr_XgalK is the name of the BAC. 
“X” stands for the site of the galK in the BAC. 
galK positive 
galK negative 
 
Fig. 2. Positive selection for galK mutant clones and negative selection for 
WT/mutant/rescue clones. SW102 bacteria with WT, galK mutant (geneX replaced by galK 
gene), geneY mutant (galK replaced by mutated geneX), or rescue (geneX restored) BACs 
were plated on MacConkey agar with galactose as the sole source of carbon and antibiotic. 
Recombinant BAC clones containing galK appear as red colonies; clones with WT BAC, 
geneY mutant BAC, or rescue BAC appear as white/colorless colonies. 
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Fig. 3. PCR verification. A. PCR using galK primers with galK mutant clones (geneX replaced 
by galK – clones produced from Fig. 1. 4) as template. 1.3kb band indicates presence of galK 
gene: Lanes 1-3 are galK mutant clones #1-3, respectively; Lane 4 is original BAC (negative 
control); Lane 5 is pgalK (positive control). B. PCR using primers that override the 
homologous sequences with galK mutant clones as template. 1.4kb band indicates presence 
of galK+BAC sequence, 300 bp band indicates BAC sequence only: Lanes 1-3 are galK mutant 
clones #1-3, respectively; Lane 4 is original BAC (positive control); Lane 5 is pgalK (negative 
control). C. PCR using galK primers with mutant clones (galK replaced by geneY) as template 
(mutant clones #1-3 were created, respectively, from galK mutant clones #1-3 in Panels 1+2). 
1.4kb band indicates presence of galK+BAC sequence: Lanes 1-3 are mutant clones #1-3, 
respectively; Lane 4 is original BAC (negative control); Lane 5 is a galK mutant clone used to 
derive a mutant clone (i.e. galK mutant clone #1 from Panels 1+2) (positive control).  
D. PCR using primers that override the homologous sequences with mutant clones as 
template. 700 bp band indicates presence of mutant gene (geneY), 300 bp band indicates  
WT BAC sequence, 1.4kb band indicates presence of galK+BAC sequence: Lanes 1-3 are 
mutant clones #1-3, respectively; Lane 4 is original BAC (positive control); Lane 5 is a galK 
mutant clone used to derive a mutant clone (positive control). All gel electrophoreses were 
on 1% agarose gels. M = 1 kb-Opti DNA Marker (ABM, Canada). Marker units are kilobases. 
3.3 Counterselection to replace the galK gene for desired mutant generation 
3.3.1 PCR to generate the DNA fragment to substitute galK gene (Fig. 1. 7a) 
Design primers with 50 bp homology flanking the desired site to be modified. This 50 bp 
homology is usually the same as that in making galK gene. Usually the mutations are 
contained in the templates. The DNA template is a WT BAC or plasmid with the gene of 
interest mutated in the required fashion. The PCR product should therefore contain the 
desired mutations. 
Forward: 5’ 50bp homology target gene (18-20 bp) 
Reverse: 5’ 50bp homology complementary strand target gene (18-20 bp) 
3.3.2 Electroporation of DNA fragment (same conditions as in Step 2.2) 
1. Both the preparation of electrocompetent cells from the SW102 harboring plasmid or 
BAC with galK gene and the activation of defective ┣ prophage recombinase are 
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necessary (Fig. 1. 7b), and the procedure is a repetition of the prepration and activation 
of electrocompetent SW102 harboring WT BAC or plasmid in Step 2.2. 
2. Transform the PCR product into electrocompetent SW102 harboring galK mutant 
plasmid or BAC by electroporation with 0.2-1 ┤g of PCR product that contains the 
desired mutation and with homology to the area flanking the galK gene (Fig. 1. 8). After 
electroporation, the bacteria will be recovered in 10 ml LB in a 50 ml baffled conical 
flask by incubating at 32°C in a shaking water bath for 4.5 hrs. This long recovery 
period serves to obtain bacteria that only contain the desired recombined BAC or 
plasmid, and thus have lost any BAC still containing the galK cassette. 
3. 1 ml of the recovery culture will be centrifuged and the pellet will be resuspended with 
M9 buffer and washed twice with M9 buffer. After second washing, the pellet will be 
resuspended in 1 ml of M9 buffer and the bacteria will be plated in a serial dilution (100 
┤l, 100 ┤l of a 1:10 dilution and 100 ┤l 1:100) onto M63 minimal media plates that contain 
glycerol, leucine, biotin, 2-deoxygalactose (DOG), and appropriate antibiotics (Fig. 1. 10). 
4. Incubate at 32°C for three days. Further verification can be accomplished by PCR 
and/or DNA sequencing (Fig. 1. 11). A name is required for any mutation. For MCMV 
BAC, we name the bacterial strain SW102_SM3fr_XY and the BAC SM3fr_XY. “X” 
stands for the site of the mutation in the BAC genome, and “Y” stands for the mutations 
(deletion, insertion, point mutation or other). For BAC mutagenesis, especially for 
making any mutation on viruses, a rescue BAC for each mutation is very important. 
3.4 Generation of rescue clone of each mutation 
The mutagenesis protocol, for some purposes, does not need to progress to this step. 
However, for some studies, especially for viral mutagenesis, it is necessary to make rescue 
viruses so that the observed phenotype can be compared and confirmed. The same galK 
method will be used to make a rescue clone that was used to generate the original mutation, 
except for starting with the mutant BAC and working backwards. 
1. The SW102_XY will be used to make electrocompetent cells, using the same procedure 
as in Step 2.2. 
2. The competent cells will be electroporated with the PCR product of galK cassette (exactly 
the same cassette as the one produced in Step 2.1), which will result in SW102_XgalK.  
3. After growth and verification, SW102_XgalK will undergo electrocompetent cell 
preparation, as before, and electroporated with a DNA fragment that will be made 
using the same primers, but with a template that contains no mutation. 
4. Therefore the rescue clone is made using the backwards steps. We can also give a name 
such as SW102_XYRes for the bacteria. 
3.5 Maxipreparation of BAC DNA (all recombinant clones) 
Now, all of the plasmids or BAC DNA can be isolated for any purpose, e.g. in the case of 
herpesviruses, the BAC DNA needs to be isolated and purified for making viruses. Since BAC 
is usually a large DNA vector, its isolation and identification are different from that of regular 
plasmid protocol. Fortunately, several high quality kits have been commercially available for 
preparation of BAC DNA on a large-scale. In this case, the BAC DNA needs to be extracted 
from the SW102_XY (or SW102_X as a control) for transfection and production of virus. 
1. Select a colony to inoculate 5 ml LB with chloramphenicol (final concentration  
12.5 mg/ml) and shake overnight in an incubator at 32ºC. 
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2. The following day, save 200-500 µl of culture to make a stock (see below), and add the 
remainder of the 5 ml culture to 500 ml LB with chloramphenicol (final concentration 12.5 
mg/ml) and shake overnight in an incubator at 32ºC. To make a bacterial stock, add 100% 
glycerol to the saved culture to a final concentration of 15% glycerol and store at -80ºC. 
3. Use the Nucleobond Maxiprep BAC DNA isolation kit (Clontech Laboratories Inc., CA) 
to extract BAC DNA from the culture. Because of their large size, BAC DNAs need to be 
handled in a way that avoids any harsh physical shearing force, including vortexing or 
passing quickly through fine pipette tips. Freeze-and-thaw should also be avoided.  
4. The final DNA products are resuspended in 250 ┤l sterile ddH2O and quantified by 
spectroscopy. 
5. BAC DNA solutions should always be stored at 4°C. 
3.6 Verification of BAC DNA integrity [Varicella zoster virus (VZV) is used as an 
example in the following sections] 
1. Digest 3 µg of mutant BAC DNA, with WT digestion in parallel as control, with 20 U of 
restriction enzyme. Example: 3 µl of 1 µg/µl VZV WT BAC DNA, 20 U (1 µl) HindIII 
restriction enzyme (New England Biolabs, MA), 1 µl 10X NEBuffer 2 (New England 
Biolabs, MA), 5 µl ddH2O. 
2. Incubate overnight at 37ºC and run gel electrophoresis on 0.5% agarose gel. Fig. 4 
highlights the pattern observed when digesting WT VZV BAC, ORF7 Deletion VZV 
BAC, and ORF7 Rescue VZV BAC, respectively. 
M 
         12-                             5-                                            2-          1.65-                       1- 
WT D R 
 
Fig. 4. Verification of BAC DNA integrity. For all BACs, 3 µg BAC DNA was digested with 
20 U HindIII restriction enzyme overnight at 37ºC and ran electrophoretically on 0.5% 
agarose gel. M: 1 kb Plus DNA Ladder (Invitrogen, CA), units are kb; WT: VZV WT BAC 
DNA; D: VZV ORF7 Deletion BAC DNA; R: VZV ORF7 Rescued BAC DNA. 
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3.7 Transfection of BAC DNA for virus production 
BAC DNA from Maxi-preparations is transfected into human cells (e.g. MeWo, ARPE-19) 
using the FuGene 6 transfection kit (Roche, Indianapolis, IN), according to manufacturer’s 
standard protocol. 1.5 ┤g of BAC DNA and 6 ┤l of transfection reagent are used for a single 
reaction in one well of 6-well tissue culture plates. Highly concentrated (>250 ┤g/┤l) BAC 
DNA solutions are viscous, and BAC DNA molecules easily precipitate out of the solution 
when added to transfection reagent solutions. When such precipitation becomes visible, it is 
irreversible; predictably, the results of the transfection assays are often poor. Therefore, pre-
dilute each BAC DNA before gently mixing it with the transfection reagent.  
1. For each reaction, 1.5 ┤g of BAC DNA is diluted in serum-free medium, and the volume 
of DNA solution is adjusted to 50 ┤l with the serum-free medium. 
2. For each reaction, 6 µl of transfection reagent is combined with 94 µl of medium. 
3. Using pipettor tips, gently stir the DNA solution into the transfection reagent. 
4. Incubate mixture for 25 minutes at room temperature. 
5. Add DNA-transfection reagent solution to culture plate. 
3.8 Infected cell culture 
1. Transfected cells are grown in a 6-well tissue culture plate in 2 ml DMEM 
supplemented with 10% fetal calf serum, 100U of penicillin-streptomycin/ml, and 2.5 
ug of amphotericin B/ml [47, 48]. 
2. Upon visualization of infection, Usually viral plaques will be developed and visualized 
under microscopy as shown in Fig. 5. 
 
Fig. 5. Generation of VZV by transfection of viral BAC DNA. Human ARPE-19 cells were 
chemically transfected with WT VZV BAC DNA. Infected cells expressing EGFP (inserted into 
BAC vector) and form green plaques. One plaque is visualized by fluorescent microscope.  
3.9 Summary of the protocol 
The protocol of the seamless recombination with specific selection cassette in PCR-based 
site-directed mutagenesis is summarized in Fig. 1, using BAC as an example. Firstly, SW102 
E. coli is made to be electrocompetent (E.C.) (Fig. 1. 1a). Then, the WT BAC is electroporated 
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into the electrocompetent SW102 (Fig. 1. 1b). The galK cassette is prepared by PCR with a set 
of primers conferring sequence homology to the viral BAC sequences flanking geneX (Fig. 1. 
2a). Electrocompetent SW102 E. coli harboring WT viral BAC is prepared, and the defective ┣ 
phage recombination system is activated by shaking in a 42ºC water bath for 15 minutes 
(Fig. 1. 2b). The galK-expressing cassette is electroporated into recombination-activated 
SW102 strain harboring WT BAC (Fig. 1. 3). Upon homologous recombination, geneX is 
replaced by galK (Fig. 1. 4). The presence of galK in the recombinant clones is selected by 
growing bacteria on M63 plates with galactose as the sole source of carbon and the proper 
antibiotic. Colonies are then selected to screen on MacConkey agar with galactose as the sole 
source of carbon. The galK-containing recombinant clones will produce red colonies on 
MacConkey agar with galactose (Fig. 1. 5). Fig. 2 highlights the easily perceived selection 
model of the galK mutagenesis approach, as red colonies are indicative of galK presence, 
whereas the colorless colonies do not express galK. A red colony from the screening process 
is chosen to verify by PCR and continue on with the rest of the protocol (Fig. 1. 6). A geneY 
cassette (PCR cassette containing desired mutation in geneX, referred to as geneY, or other 
gene) is prepared by PCR with primers conferring homologous sequences to the galK region 
in the mutant BAC (Fig. 1. 7a). From the red colony, SW102 harboring galK mutant BAC, 
selected in Step 5, are prepared to be electrocompetent and recombination-activated as in 
Fig. 1. 2b (Fig. 1. 7b). The geneY cassette is electroporated into the electrocompetent and 
recombination-activated SW102 strain harboring galK mutant clone (Fig. 1. 8). Upon 
homologous recombination, galK is replaced by geneY (Fig. 1. 9). Bacteria are grown on M63 
with glycerol, DOG and antibiotic agar plates to counterselect for recombinant mutant BACs 
(Fig. 1. 10). Since the recombinants will now lack galK, selection takes place against the galK 
cassette by resistance to 2-deoxy-galactose (DOG) on minimal plates with glycerol as the 
carbon source (Fig. 1. 10) [27]. DOG is harmless, unless phosphorylated by functional galK. 
Phosphorylation by galK turns DOG into 2-deoxy-galactose-1-phosphate, a toxic intermediate 
[44]. From the resulting DOG-resistant colonies, some will be background colonies, where the 
bacteria have lost the galK cassette by a deletion, and the rest will be truly recombinant clones. 
Therefore, recombinant colonies containing the modified gene sequence can be quickly 
selected due to the negative or counterselection of colonies with galK, which makes this 
timesaving system also highly efficient. The resulting recombinant clones will be verified by 
PCF (Fig. 3) and restriction enzyme digestion (Fig. 4). Transfection of the mutated viral BAC 
into mammalian cells then produces an infectious virus (Fig. 5) [43].  
4. Discussion 
Molecular cloning vectors were once plasmids that could only carry and replicate small-
sized DNA and have been developed to yeast artificial chromosome (YAC), bacterial 
artificial chromosome (BAC) and bacteriophage P1-derived artificial chromosome (PAC) 
that can carry and replicate large DNA molecules. Based on these vectors, recombineering 
techniques have contributed profoundly to investigating protein structure, function, and to 
elucidate viral pathogenesis, among others. However, the methods for BAC mutagenesis we 
use today were not easily attained as the large size of BACs posed a serious obstacle for 
their exact manipulation, as is required for viral research. To overcome these obstacles, 
techniques were developed that utilized the power of homologous recombination in order 
to create recombinant viruses, with the ability to safeguard every step in the process. We can 
now replace, and therefore delete, large DNA fragments with selectable marker cassettes, 
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and within the described galK mutagenesis system there is also a counterselection model as 
well, using new systems that circumvent the problems associated with conventional genetic 
engineering as there is no longer a size restriction as seen when using restriction enzymes or 
other previous methods [37,44].  
As previously mentioned, the generation of both the mutant and rescued BACs within the 
galK system take advantage of counterselection. For all such counterselection schemes, any 
event that leads to the loss of the counterselectable marker during negative selection will 
mean the survival of unwanted bacteria, leading to trace amounts of background. In the 
galK system, BAC replication appears to be the epicenter of background formation [41]. 
Despite the reliable stability of BACs, rare deletions do occur during counterselection, 
leading to background. Although there is spontaneous deletion background, it is 
insignificant relative to the great percentage of correct recombinants due to the high 
frequency of recombination from the ┣ prophage system. Furthermore, increasing the length 
of homology arms used for recombination can increase specific homologous recombination 
efficient and reduce the number of background deletions relative to the increased number of 
correct recombinants. 
So far, most mutagenesis studies using the BAC system require generation of a rescue clone 
of the mutation to assure that no mutations occur anywhere other than the target site. The 
procedure of making rescue BAC DNA requires an original DNA fragment to be inserted 
back into the viral genome. This can be achieved by PCR amplification of the DNA fragment 
along with homology arms flanking the mutated region and insertion of the amplified 
fragment back into the mutant genome by homologous recombination. This method is 
analogous to procedure for generating recombinant mutants, as the only difference lies in 
the fact that there is no designed point mutation or deletion achieved via PCR. Antibiotic-
resistance selection systems are the most extensively used method, however, removal of the 
antibiotic-resistance gene is not only necessary for functional analysis of a viral gene, but 
also required for preparing viral vaccine strains. The galK mutagenesis protocol outlined 
above is a seamless mutagenesis model because there is no requirement for further excision 
of the flanking homologous sequences that contain LoxP or FRT that might cause the loss of 
viral DNA during the process of making viruses in mammalian cells, as there is in 
antibiotic-resistance based mutagenesis. Thus, the process of making mutants by the above-
mentioned protocol is considered to be accurate as there are no unintended mutations that 
could occur as a result, and even if there are, the strong counterselection strategy and 
troubleshooting strategies help to clear any background mutants. 
5. Conclusion 
These and other various advantages are responsible for the increased efficacy of the 
homologous recombination-based method for the construction of recombinant viruses. 
Outdated procedures for traditional mutagenesis, including molecular cloning that depends 
on preparations of vector and inserted DNA fragments and ligations, are laboring and time-
intensive. The development of the Bacterial Artificial Chromosome (BAC) clone of large 
DNA viruses was an innovation that advanced the viral mutagenesis field to a new peak for 
global mutation and pathogenesis studies as any required mutation can be easily and 
rapidly achieved by the novel recombineering method for construction of recombinant 
viruses by homologous recombination. This mutagenesis method has led to a great 
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expansion in the field of molecular research, whereas galK mutagenesis takes this 
recombineering strategy to a heightened level of accuracy and, therefore, results. 
6. Future directions 
The amount of biomedical research utilizing plasmids and BACs has grown rapidly during 
the past decade, resulting in invaluable knowledge about protein structure and function, 
viral pathogenesis, vaccine development and gene therapy. Since the construction of the 
first herpesvirus BAC 12 years ago, BACs have been generated for all major human and 
animal herpesviruses, and this technology has greatly facilitated genetic and functional 
studies of herpesviruses, because recombinant viruses, especially herpesviruses, were 
previously difficult to produce due to their large size. Soon, we may have BACs for not only 
all herpesviruses [27], but all DNA viruses, as well as novel global mutational studies for 
several virus BACs thanks to accurate and seamless mutagenesis procedures such as the 
galK recombineering protocol. Global and local studies of virus pathogenesis should help 
identify new antiviral targets and produce more effective and safe vaccines. In short, future 
virus BAC-based mutagenesis studies achieved by the seamless galK mutagenesis protocol 
should help provide exciting new discoveries about viral pathogenesis, protein structure 
and function, as well as therapeutics for both viral and non-viral diseases. 
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